HandFoot Skin Reaction is Associated with the Clinical Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Sorafenib

被引:39
|
作者
Nakano, Kazuhiko [1 ]
Komatsu, Kenji [1 ]
Kubo, Taro [1 ]
Natsui, Shinsuke [1 ]
Nukui, Akinori [1 ]
Kurokawa, Shinsuke [1 ]
Kobayashi, Minoru [1 ]
Morita, Tatsuo [1 ]
机构
[1] Jichi Med Univ, Dept Urol, Shimotsuke, Tochigi 3290498, Japan
关键词
HandFoot skin reaction; renal cell carcinoma; sorafenib; tyrosine kinase inhibitor; KINASE INHIBITORS SORAFENIB; JAPANESE PATIENTS; EFFICACY; SAFETY; HYPERTENSION; MONOTHERAPY; TOXICITIES; SURVIVAL; THERAPY;
D O I
10.1093/jjco/hyt110
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To elucidate whether HandFoot skin reaction could become a biomarker of clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib, we retrospectively examined the association between the HandFoot skin reaction and the clinical outcome in metastatic renal cell carcinoma patients treated with sorafenib. Thirty-six Japanese metastatic renal cell carcinoma patients treated with sorafenib were enrolled and divided into the groups with or without HandFoot skin reaction. Patient characteristics, best tumor response, progression-free survival and adverse events were investigated and compared between these two groups. A sorafenib-induced HandFoot skin reaction in metastatic renal cell carcinoma patients was observed at a significantly higher rate in patients in the favorable-risk group in the Memorial Sloan-Kettering Cancer Center risk classification, and with Eastern Cooperative Oncology Group Performance Status of one or less, prior nephrectomy, higher hemoglobin, lower lactate dehydrogenase and lower C-reactive protein. The mean best tumor response was significantly better in the group with HandFoot skin reaction (16.7) than that in the group without it (17.9; P 0.001). The median progression-free survival was significantly longer in the group with HandFoot skin reaction (4.6 months) than that in the group without it (1.5 months; P 0.002). In multivariate analysis, only HandFoot skin reaction was shown to be a predictive factor of progression-free survival (hazard ratio 0.312, P 0.010). A sorafenib-induced HandFoot skin reaction in metastatic renal cell carcinoma patients emerged at a significantly higher rate in patients in the favorable-risk group in the Memorial Sloan-Kettering Cancer Center risk classification and was significantly associated with best tumor response and progression-free survival, suggesting that HandFoot skin reaction might be an independent predictive factor for clinical outcome in metastatic renal cell carcinoma patients treated with sorafenib.
引用
收藏
页码:1023 / 1029
页数:7
相关论文
共 50 条
  • [31] Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma
    Schlemmer, Marcus
    Spek, Annabel
    Rodler, Severin
    Schott, Melanie
    Casuscelli, Jozefina
    Staehler, Michael
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (03)
  • [32] Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma
    Ye, Ding-Wei
    Zhang, Hai-Liang
    ONCOTARGETS AND THERAPY, 2014, 7 : 925 - 935
  • [33] Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study
    Qin, Shukui
    Bi, Feng
    Jin, Jie
    Cheng, Ying
    Guo, Jun
    Ren, Xiubao
    Huang, Yiran
    Tarazi, Jamal
    Tang, Jie
    Chen, Connie
    Kim, Sinil
    Ye, Dingwei
    ONCOTARGETS AND THERAPY, 2015, 8 : 1363 - 1373
  • [34] Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib
    Zhang, Hai-Liang
    Zhu, Yao
    Wang, Chao-Fu
    Yao, Xu-Dong
    Zhang, Shi-Lin
    Dai, Bo
    Shen, Yi-Jun
    Zhu, Yi-Ping
    Shi, Guo-Hai
    Ye, Ding-Wei
    INTERNATIONAL JOURNAL OF UROLOGY, 2011, 18 (06) : 422 - 430
  • [35] A Phase 1 Study of Everolimus and Sorafenib for Metastatic Clear Cell Renal Cell Carcinoma
    Harzstark, Andrea L.
    Small, Eric J.
    Weinberg, Vivian K.
    Sun, Janine
    Ryan, Charles J.
    Lin, Amy M.
    Fong, Lawrence
    Brocks, Dion R.
    Rosenberg, Jonathan E.
    CANCER, 2011, 117 (18) : 4194 - 4200
  • [36] Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients
    Chang, Wen-Tsan
    Lu, Sheng-Nan
    Rau, Kung-Ming
    Huang, Ching-Shan
    Lee, King-Teh
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2018, 34 (07): : 391 - 399
  • [37] Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
    Tamaskar, I.
    Bukowski, R.
    Elson, P.
    Ioachimescu, A. G.
    Wood, L.
    Dreicer, R.
    Mekhail, T.
    Garcia, J.
    Rini, B. I.
    ANNALS OF ONCOLOGY, 2008, 19 (02) : 265 - 268
  • [38] A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma
    Monk, Paul
    Lam, Elaine
    Mortazavi, Amir
    Kendra, Kari
    Lesinski, Gregory B.
    Mace, Thomas A.
    Geyer, Susan
    Carson, William E., III
    Tahiri, Sanaa
    Bhinder, Arvinder
    Clinton, Steven K.
    Olencki, Thomas
    JOURNAL OF IMMUNOTHERAPY, 2014, 37 (03) : 180 - 186
  • [39] Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma
    Osawa, Takahiro
    Kojima, Takahiro
    Hara, Tomohiko
    Sugimoto, Mikio
    Eto, Masatoshi
    Takeuchi, Ario
    Minami, Keita
    Nakai, Yasutomo
    Ueda, Kosuke
    Ozawa, Michinobu
    Uemura, Motohide
    Miyauchi, Yasuyuki
    Ohba, Kojiro
    Suzuki, Toshiro
    Anai, Satoshi
    Shindo, Tetsuya
    Kusakabe, Naohisa
    Tamura, Keita
    Komiyama, Motokiyo
    Goto, Takayuki
    Yokomizo, Akira
    Kohei, Naoki
    Kashiwagi, Akira
    Murakami, Masaya
    Sazuka, Tomokazu
    Yasumoto, Hiroaki
    Iwamoto, Hideto
    Mitsuzuka, Koji
    Morooka, Daichi
    Shimazui, Toru
    Yamamoto, Yoshiaki
    Ikeshiro, Suguru
    Nakagomi, Hiroshi
    Morita, Ken
    Tomida, Ryotaro
    Mochizuki, Tango
    Inoue, Takamitsu
    Kitamura, Hiroshi
    Yamada, Shuhei
    Ito, Yoichi M.
    Murai, Sachiyo
    Nishiyama, Hiroyuki
    Shinohara, Nobuo
    CANCER SCIENCE, 2020, 111 (07) : 2460 - 2471
  • [40] Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
    Motzer, R. J.
    Escudier, B.
    Bukowski, R.
    Rini, B. I.
    Hutson, T. E.
    Barrios, C. H.
    Lin, X.
    Fly, K.
    Matczak, E.
    Gore, M. E.
    BRITISH JOURNAL OF CANCER, 2013, 108 (12) : 2470 - 2477